Guangju Meng

Guangju Meng

Auto-generated profile, based on publicly available information

Guangju Meng

Taian Cent Hosp, Dept Infect Dis, Tai An, Shandong, Peoples R China

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2017 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
PWPeng Wang
Peng Wang
LCLaifei Cheng
Laifei Cheng
YZYani Zhang
Yani Zhang
LZLitong Zhang
Litong Zhang

18 August 2021 in Advances in Clinical and Experimental Medicine
Verified
Journal Article
Open access
CNCuifang Nie
Cuifang Nie
GMGuangju Meng
Guangju Meng
YWYongyun Wu
Yongyun Wu
LLLi Liu
Li Liu
LCLi Chen
Li Chen
YHYan Hu
Yan Hu
Background. MicroRNA (miR) influences the biological activities of cirrhotic patients with recurrent portal hypertension. Objectives. The current study was designed to investigate risk factors related to the survival of cirrhosis patients and assessed the possibility of using miR-9a-5p predictability to prevent post-treatment portal hypertension. Materials and methods. Patients with portal hypertension due to liver cirrhosis treated from January 2015 to September 2016 were included in this study. Patients without relapse after treatment were selected as the success group while patients with relapse after treatment were selected as the recurrence group. Serum samples from healthy people were also collected. The blood indexes of the 2 groups of patients before and after treatment were compared and the miR-9a-5p serum level in each group was determined. The Kaplan-Meier method was applied to analyze three-year survival, Cox univariate regression was used to analyze the risk factors for recurrence of cirrhotic portal hypertension, and the receiver operating characteristic curve (ROC) was used to evaluate the diagnostic value of serum miR-9a-5p, total bilirubin (TBIL) and platelet (PLT) levels in patients with recurrence. Results. The miR-9a-5p level in the recurrence group was higher than that in the success group after treatment. In patients with recurrence, the miR-9a-5p level was negatively correlated with red blood cell count, TBIL, white blood cell count, and PLT count, and positively correlated with albumin. The miR-9a-5p, TBIL and PLT are potential markers of recurrent portal hypertension in liver cirrhosis. The miR-9a-5p had the highest area under the curve (AUC) value in patients with relapse. Conclusions. The miR-9a-5p is a risk factor for the recurrence of cirrhotic portal hypertension after treatment. It may be used as a marker of recurrence, and so has potential clinical value for the diagnosis and treatment of recurrent portal hypertension.